Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa

Blood

Volumn 117, Issue 14, 2011, Pages 3912-3920

  Al Tamimi, Mohammad ^a   Grigoriadis, George ^a,b   Tran, Huy ^b,c   Paul, Eldho ^a   Servadei, Patricia ^c   Berndt, Michael C ^d   Gardiner, Elizabeth E ^a   Andrews, Robert K ^a  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; COLLAGEN; DABIGATRAN; ENOXAPARIN; GLYCOPROTEIN VI; HIRUDIN; ILOMASTAT; METALLOPROTEINASE INHIBITOR; RIVAROXABAN; SNAKE VENOM; THROMBIN INHIBITOR;

ARTICLE; BLOOD CLOTTING; DISSEMINATED INTRAVASCULAR CLOTTING; HUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SNAKE; THROMBOCYTE; THROMBOCYTOPENIA;

EID: 79953819362     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-08-301523     Document Type: Article

References (57)

1. Yip J, Shen Y, Berndt MC, Andrews RK. Primary platelet adhesion receptors. IUBMB Life. 2005; 57(2): 103-108. (Pubitemid 40632300)
2. Gailani D, Renne T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb Vasc Biol. 2007; 27(12): 2507-2513. (Pubitemid 350158899)
3. Mackman N, Tilley RE, Key NS. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol. 2007; 27(8): 1687-1693. (Pubitemid 47207163)
4. Johne J, Blume C, Benz PM, et al. Platelets promote coagulation factor XII-mediated proteolytic cascade systems in plasma. Biol Chem. 2006; 387(2): 173-178. (Pubitemid 43221830)
5. Walsh PN. Platelet coagulation-protein interactions. Semin Thromb Hemost. 2004; 30(4): 461-471. (Pubitemid 39180721)
6. Jung SM, Moroi M. Platelet glycoprotein VI. Adv Exp Med Biol. 2008; 640: 53-63.
7. Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood. 2003; 102(2): 449-461. (Pubitemid 36841960)
8. Massberg S, Gawaz M, Gruner S, et al. A crucial role of glycoprotein VI for platelet recruitment to the injured arterial wall in vivo. J Exp Med. 2003; 197(1): 41-49. (Pubitemid 36110256)
9. Schulte V, Reusch HP, Pozgajova M, Varga-Szabo D, Gachet C, Nieswandt B. Two-phase antithrombotic protection after anti-glycoprotein VI treatment in mice. Arterioscler Thromb Vasc Biol. 2006; 26(7): 1640-1647. (Pubitemid 44288995)
10. Ohlmann P, Hechler B, Ravanat C, et al. Ex vivo inhibition of thrombus formation by an antiglycoprotein VI Fab fragment in non-human primates without modification of glycoprotein VI expression. J Thromb Haemost. 2008; 6(6): 1003-1011. (Pubitemid 351689923)
11. Munnix IC, Strehl A, Kuijpers MJ, et al. The glycoprotein VI-phospholipase Cgamma2 signaling pathway controls thrombus formation induced by collagen and tissue factor in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2005; 25(12): 2673-2678. (Pubitemid 43732296)
12. Heemskerk JW, Siljander P, Vuist WM, et al. Function of glycoprotein VI and integrin alpha2beta1 in the procoagulant response of single, collagen-adherent platelets. Thromb Haemost. 1999; 81(5): 782-792. (Pubitemid 29216567)
13. Siljander P, Farndale RW, Feijge MA, et al. Platelet adhesion enhances the glycoprotein VIdependent procoagulant response: involvement of p38 MAP kinase and calpain. Arterioscler Thromb Vasc Biol. 2001; 21(4): 618-627. (Pubitemid 32323397)
14. Heemskerk JW, Kuijpers MJ, Munnix IC, Siljander PR. Platelet collagen receptors and coagulation: a characteristic platelet response as possible target for antithrombotic treatment. Trends Cardiovasc Med. 2005; 15(3): 86-92. (Pubitemid 41021731)
15. Kempton CL, Hoffman M, Roberts HR, Monroe DM. Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations. Arterioscler Thromb Vasc Biol. 2005; 25(4): 861-866. (Pubitemid 40463882)
16. Gardiner EE, Arthur JF, Kahn ML, Berndt MC, Andrews RK. Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase. Blood. 2004; 104(12): 3611-3617. (Pubitemid 39564435)
17. Stephens G, Yan Y, Jandrot-Perrus M, Villeval JL, Clemetson KJ, Phillips DR. Platelet activation induces metalloproteinase-dependent GPVI cleavage to down-regulate platelet reactivity to collagen. Blood. 2005; 105(1): 186-191. (Pubitemid 40053081)
18. Bergmeier W, Rabie T, Strehl A, et al. GPVI down-regulation in murine platelets through metalloproteinase-dependent shedding. Thromb Haemost. 2004; 91(5): 951-958. (Pubitemid 38647499)
19. Andrews RK, Karunakaran D, Gardiner EE, Berndt MC. Platelet receptor proteolysis: a mechanism for downregulating platelet reactivity. Arterioscler Thromb Vasc Biol. 2007; 27(7): 1511-1520. (Pubitemid 46986104)
20. Bender M, Hofmann S, Stegner D, et al. Differentially regulated GPVI ectodomain shedding by multiple platelet-expressed proteinases. Blood. 2010; 116(17): 3347-3355.
21. Gardiner EE, Karunakaran D, Shen Y, Arthur JF, Andrews RK, Berndt MC. Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. J Thromb Haemost. 2007; 5(7): 1530-1537. (Pubitemid 46965384)
22. Al-Tamimi M, Mu FT, Moroi M, Gardiner EE, Berndt MC, Andrews RK. Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets. 2009; 20(3): 143-149.
23. Al-Tamimi M, Mu FT, Arthur JF, et al. Antiglycoprotein VI monoclonal antibodies directly aggregate platelets independently of Fcgamma-RIIa and induce GPVI ectodomain shedding. Platelets. 2009; 20(2): 75-82.
24. Skinner MP, Lucas CM, Burns GF, Chesterman CN, Berndt MC. GMP-140 binding to neutrophils is inhibited by sulfated glycans. J Biol Chem. 1991; 266(9): 5371-5374. (Pubitemid 21909502)
25. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007; 98(1): 155-162. (Pubitemid 47078782)
26. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007; 64(3): 292-303. (Pubitemid 47283865)
27. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate, a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103(6): 1116-1127.
28. Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939, an oral, direct Factor Xa inhibitor. J Thromb Haemost. 2005; 3(3): 514-521. (Pubitemid 41632877)
29. Liesenfeld KH, Schafer HG, Troconiz IF, Tillmann C, Eriksson BI, Stangier J. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol. 2006; 62(5): 527-537. (Pubitemid 44571573)
30. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361(12): 1139-1151.
31. Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost. 2007; 5(4): 886-888. (Pubitemid 46563600)
32. Spinler SA, Wittkowsky AK, Nutescu EA, Smythe MA. Anticoagulation monitoring part 2: unfractionated heparin and low-molecular-weight heparin. Ann Pharmacother. 2005; 39(7): 1275-1285. (Pubitemid 40943181)
33. Robert S, Ghiotto J, Pirotte B, et al. Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs? Pharmacol Res. 2009; 59(3): 160-166.
34. Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, Owings JT. Comparing direct thrombin inhibitors using aPTT, ecarin clotting times, and thrombin inhibitor management testing. Ann Pharmacother. 2004; 38(9): 1383-1388. (Pubitemid 39100188)
35. Gardiner EE, Al-Tamimi M, Mu FT, et al. Compromised ITAM-based platelet receptor function in a patient with immune thrombocytopenic purpura. J Thromb Haemost. 2008; 6: 1175-1182. (Pubitemid 351859128)
36. Gardiner EE, Karunakaran D, Arthur JF, et al. Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: de-ITAM-izing FcgammaRIIa. Blood. 2008; 111(1): 165-174.
37. Verma AK. Dabigatran etexilate: a new thrombin inhibitor. Med J Aust. 2010; 192(7): 407-412.
38. Fassiadis N. Rivaroxaban, the first oral, direct factor Xa inhibitor. Expert Opin Pharmacother. 2009; 10(18): 2945-2946.
39. Borensztajn K, Peppelenbosch MP, Spek CA. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. Trends Mol Med. 2008; 14(10): 429-440.
40. Dalainas I. Pathogenesis, diagnosis, and management of disseminated intravascular coagulation: a literature review. Eur Rev Med Pharmacol Sci. 2008; 12(1): 19-31. (Pubitemid 351436167)
41. Levi M. Disseminated intravascular coagulation. Crit Care Med. 2007; 35(9): 2191-2195. (Pubitemid 47326459)
42. Al-Tamimi M, Gardiner EE, Thom JY, et al. Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke. Stroke. 2011; 42(2): 498-500.
43. Jangouk P, Dehmel T, Meyer Zu Horste G, Ludwig A, Lehmann HC, Kieseier BC. Involvement of ADAM10 in axonal outgrowth and myelination of the peripheral nerve. Glia. 2009; 57(16): 1765-1774.
44. Ramakrishnan V, DeGuzman F, Bao M, Hall SW, Leung LL, Phillips DR. A thrombin receptor function for platelet glycoprotein Ib-IX unmasked by cleavage of glycoprotein V. Proc Natl Acad Sci U S A. 2001; 98(4): 1823-1828. (Pubitemid 32165582)
45. Rauch BH, Bretschneider E, Braun M, Schror K. Factor Xa releases matrix metalloproteinase-2 (MMP-2) from human vascular smooth muscle cells and stimulates the conversion of pro-MMP-2 to MMP-2: role of MMP-2 in factor Xa-induced DNA synthesis and matrix invasion. Circ Res. 2002; 90(10): 1122-1127. (Pubitemid 34627912)
46. Choi WS, Jeon OH, Kim DS. CD40 ligand shedding is regulated by interaction of MMP-2 and platelet integrin alphallbbeta3. J Thromb Haemost. 2010; 8(6): 1364-1371.
47. Massberg S, Konrad I, Bultmann A, et al. Soluble glycoprotein VI dimer inhibits platelet adhesion and aggregation to the injured vessel wall in vivo. FASEB J. 2004; 18(2): 397-399.
48. Bultmann A, Herdeg C, Li Z, et al. Local delivery of soluble platelet collagen receptor glycoprotein VI inhibits thrombus formation in vivo. Thromb Haemost. 2006; 95(5): 763-766.
49. Gruner S, Prostredna M, Koch M, et al. Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice. Blood. 2005; 105(4): 1492-1499. (Pubitemid 40223665)
50. Miura Y, Takahashi T, Jung SM, Moroi M. Analysis of the interaction of platelet collagen receptor glycoprotein VI (GPVI) with collagen: a dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen. J Biol Chem. 2002; 277(48): 46197-46204. (Pubitemid 35417611)
51. Wong PC, Jiang X. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin. Thromb Haemost. 2010; 104(2): 302-310.
52. Romualdi E, Ageno W. Oral Xa inhibitors. Hematol Oncol Clin North Am. 2010; 24(4): 727-737.
53. Lee CJ, Badhwar G, Ansell JE. Oral lla inhibitors. Hematol Oncol Clin North Am. 2010; 24(4): 739-753.
54. Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010; 103: 572-585.
55. Bigalke B, Stellos K, Weig HJ, et al. Regulation of platelet glycoprotein VI (GPVI) surface expression and of soluble GPVI in patients with atrial fibrillation (AF) and acute coronary syndrome (ACS). Basic Res Cardiol. 2009; 104(3): 352-357.
56. Endres K, Fahrenholz F. Upregulation of the alpha-secretase ADAM10: risk or reason for hope? FEBS J. 2010; 277(7): 1585-1596.
57. Lacy MQ. Arterial thrombosis complicates myeloma? Blood. 2010; 116(1): 2-3.